Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 5/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.48 |
| ▸ | CPA1 | P15085 | 2/20 | 0.47 |
| ▸ | CPA2 | P48052 | 2/20 | 0.47 |
| ▸ | CPA4 | Q9UI42 | 2/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7619363 | 0.82 | ACE2 (0.68) | ACE2MME | |
| SCHEMBL7619360 | 0.82 | ACE2 (0.68) | ACE2MME | |
| SCHEMBL7620840 | 0.82 | ACE2 (0.68) | ACE2MME | |
| SCHEMBL1764577 | 0.79 | ERAP2 (0.43) | ANPEPERAP2MMELAP3ERAP1 | |
| SCHEMBL1764058 | 0.77 | ANPEP (0.57) | ANPEPERAP2MMELAP3ERAP1 | |
| SCHEMBL1764559 | 0.77 | ACE2 (0.46) | ANPEPERAP2CPA1CPA2CPA4 | |
| SCHEMBL1764401 | 0.76 | ACE2 (0.60) | ACE2MME | |
| SCHEMBL6926440 | 0.74 | ACE2 (0.57) | ACE2MME | |
| SCHEMBL5916386 | 0.73 | ACE2 (0.56) | ANPEPERAP2CPA1CPA2CPA4 | |
| SCHEMBL24991305 | 0.72 | ANPEP (0.54) | ANPEPERAP2CPA1CPA2CPA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2018-11-20 | — | — | US | disclosed |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS (FR) | 2014-06-12 | — | — | US | disclosed |
| US-8703747-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | ANPEP 2038/4885ERAP2 4566/4885CPA1 3555/4885 |
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | OPRM1, HRH3, HRH4 | ANPEP 2062/4885ERAP2 4514/4885CPA1 3474/4885 |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | ANPEP 2062/4885ERAP2 4514/4885CPA1 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.